比利時(shí)Euroscreen S.A.  www.euroscreen.com
Euroscreen S.A. ，生物技術(shù)公司，從事鑒定及人類受體的藥物開發(fā)項(xiàng)目的生命科學(xué)行業(yè)。Euroscreen開發(fā)和藥物篩選的工具和技術(shù)的基礎(chǔ)上的克隆和表達(dá)的重組蛋白受體和其他參與細(xì)胞信號(hào)，是ICOS、人類基因組科學(xué)公司以及CCR5非抗體治療方面專利的排他許可權(quán)人。Euroscreen is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs.
Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, Euroscreen is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.
Euroscreen pursues a dual business model strategy of combining its internal programs on high value targets (Euroscreen DRUG DISCOVERY) with its fully dedicated Business Unit (Euroscreen FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.
Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2. See Patent Portfolio
Euroscreen has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Novartis and Pfizer. See our Track Record